Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Oral Maxillofac Surg Clin North Am ; 28(4): 497-506, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27595478

ABSTRACT

Most patients with coronary artery disease and peripheral vascular disease are on long-term antiplatelet therapy and dual therapy. Achieving a balance between ischemic and bleeding risk remains an important factor in managing patients on antiplatelet therapy. For most outpatient surgical procedures, maintenance and continuation of this therapy are recommended. Consultation with the patient's cardiologist, physician, and/or vascular surgeon is always recommended before interrupting or withholding this treatment modality.


Subject(s)
Aspirin/administration & dosage , Oral Surgical Procedures , Platelet Aggregation Inhibitors/administration & dosage , Ticlopidine/analogs & derivatives , Aspirin/therapeutic use , Clopidogrel , Coronary Artery Disease/drug therapy , Humans , Medication Therapy Management , Peripheral Vascular Diseases/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Ticlopidine/administration & dosage , Ticlopidine/therapeutic use
2.
Conn Med ; 78(3): 133-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24772828

ABSTRACT

We evaluated the clinical value of a single measurement of high-sensitivity C-reactive protein (hs- CRP) in patients presenting to the emergency department with chest pain. We screened 408 consecutive patients of whom 292 comprised the final cohort for this study. Hs-CRP measured in the emergency department (ED) in patients presenting with chest pain and admitted for evaluation of acute myocardial infarction was neither sensitive nor specific in predicting acute myocardial infarction, myocardial ischemia on SPECT imaging, need for coronary revascularization, or cardiovascular or all-cause rehospitalization at 30 days. In addition, use of a specific CRP cut off >1 was not associated with an increase in all-cause rehospitalization at 30 days.


Subject(s)
C-Reactive Protein/analysis , Chest Pain/blood , Emergency Service, Hospital/organization & administration , Myocardial Ischemia/blood , Myocardial Ischemia/diagnosis , Acute Disease , Aged , Cardiovascular Agents/administration & dosage , Comorbidity , Female , Humans , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/diagnosis , Patient Readmission/statistics & numerical data , Percutaneous Coronary Intervention/statistics & numerical data , Sensitivity and Specificity , Severity of Illness Index
3.
Heart Lung Circ ; 19(10): 601-5, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20655278

ABSTRACT

BACKGROUND: Current data suggest an excellent outcome for patients with Tako-tsubo cardiomyopathy (TC). The objectives of this study were to evaluate the long-term outcome and the prognostic implication of thrombolysis in myocardial infarction myocardial perfusion grade (TMPG) in patients with TC. METHODS: Retrospective analysis of all patients diagnosed with TC at our hospital between 2003 and 2008. RESULTS: During the five-year period, we identified 27 patients with TC out of 1374 cases of emergent left heart catheterisation (2%). Mean follow-up was 27 ± 16 months. The majority were Caucasian (81%) female (96%), postmenopausal (96%), with a mean age of 68 ± 14 years. A precipitating stressor event was found in 74% of the patients, 30% being gastrointestinal triggers. Fourteen patients (52%) reached a combined end point of all cause death, cardiogenic shock, sudden cardiac death and rehospitalisation for cardiac reasons. TMPG was abnormal in 37% cases with no correlation with the outcome. CONCLUSIONS: The long-term outcome of patients with TC is worse than previously reported. TMPG does not correlate with the outcome in TC.


Subject(s)
Takotsubo Cardiomyopathy/drug therapy , Adult , Aged , Aged, 80 and over , Antihypertensive Agents/therapeutic use , Biomarkers , Cardiac Catheterization , Chest Pain , Female , Health Status Indicators , Humans , Male , Middle Aged , Platelet Aggregation Inhibitors/therapeutic use , Prognosis , Retrospective Studies , Statistics as Topic , Takotsubo Cardiomyopathy/epidemiology , Takotsubo Cardiomyopathy/therapy , Time Factors , Treatment Outcome
4.
Conn Med ; 72(3): 143-6, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18426180

ABSTRACT

Cardiac papillary fibroelastomas are rare, usuallybenign tumors that can be detected at autopsy, during open-heart surgery, or with echocardiography. They usually arise from the cardiac valves and more commonly are found on the left side of the heart. Embolization of left-sided and tricuspid valve tumors has been well documented. This is the 1st reported case of pulmonary embolization of a papillary fibroelastoma arising from the pulmonary valve.


Subject(s)
Endocardial Fibroelastosis/pathology , Pulmonary Embolism/pathology , Pulmonary Valve/pathology , Aged, 80 and over , Female , Heart Valve Diseases/pathology , Humans
5.
Heart Lung Circ ; 15(3): 187-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16713354

ABSTRACT

Mitral annular calcification (MAC) is found in 10% of patients older than 50 years of age, and represents deposition of calcium between the basal infero-lateral ventricular wall and the posterior leaflet of the mitral valve. Caseous calcification, formed from a mixture of calcium, cholesterol and fatty acids, is an uncommon variant found on echocardiography in 0.6% of patients with MAC. The characteristic echographic appearance is of a large echo-dense structure with echo-lucent center and smooth borders. Caseous MAC carries a benign prognosis despite its impressive appearance and should not be misdiagnosed as a more serious condition such as myocardial abscess or tumor.


Subject(s)
Calcinosis/diagnostic imaging , Heart Valve Diseases/diagnostic imaging , Mitral Valve/diagnostic imaging , Aged , Aging/pathology , Calcinosis/pathology , Heart Valve Diseases/pathology , Humans , Male , Mitral Valve/pathology , Ultrasonography
6.
Heart Lung Circ ; 15(2): 148-50, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16574539

ABSTRACT

The intraaortic balloon pump (IABP) is frequently used in the management of cardiac failure in the setting of myocardial infarction or as a bridge for coronary revascularisation surgery. The IABP is usually inserted through the femoral artery. Occasionally severe aorto-iliac occlusive disease prevents the retrograde passage of the balloon, in which case an anterograde route, usually through the ascending aorta is used. We describe four patients in whom an IABP was placed through the subclavian artery by the joint efforts of cardiologists and vascular surgeons.


Subject(s)
Intra-Aortic Balloon Pumping/methods , Shock, Cardiogenic/surgery , Subclavian Artery/surgery , Aged , Anastomosis, Surgical/instrumentation , Anastomosis, Surgical/methods , Aortic Valve Stenosis/surgery , Arterial Occlusive Diseases/surgery , Cardiac Catheterization , Female , Heart Failure/surgery , Humans , Intra-Aortic Balloon Pumping/instrumentation , Male , Middle Aged , Peripheral Vascular Diseases/surgery , Treatment Outcome
7.
Conn Med ; 69(8): 457-9, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16270780

ABSTRACT

Aortic intramural hematoma (AIH) is part of the acute aortic syndrome together with aortic dissection and penetrating aortic ulcer. AIH represents up to 12% of acute aortic syndrome cases and has a clinical presentation indistinguishable from that of classic aortic dissection. A patient with AIH is presented and the diagnostic, prognostic and therapeutic implications of the disease are discussed.


Subject(s)
Aorta, Thoracic , Diagnostic Imaging , Hematoma/diagnosis , Aged , Aortic Dissection/diagnosis , Antihypertensive Agents/therapeutic use , Aortic Aneurysm, Thoracic/diagnosis , Diagnosis, Differential , Female , Hematoma/drug therapy , Humans
9.
Conn Med ; 67(10): 595-8, 2003.
Article in English | MEDLINE | ID: mdl-14677339

ABSTRACT

Paroxysmal atrial fibrillation (PAF) has a similar stroke risk when compared with chronic atrial fibrillation (CAF). Our study sought to define the incidence of warfarin use at time of admission and discharge in patients hospitalized with PAF and CAF. Anticoagulation rates upon hospital admission were 89% in the patients with CAF and 38% in patients with PAF, and increased to 100% for patients with CAF and 81% for patients with PAF at the time of hospital discharge. Despite a similar risk of stroke, patients with paroxysmal atrial fibrillation were less likely to receive long-term oral anticoagulation (AC) compared to patients with chronic atrial fibrillation.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Warfarin/therapeutic use , Aged , Chronic Disease , Comorbidity , Contraindications , Drug Utilization , Female , Hospitalization/statistics & numerical data , Humans , Incidence , Male , Practice Guidelines as Topic , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...